SOURCE: DNAPrint Genomics, Inc.

August 28, 2006 07:00 ET

DNAPrint Genomics Financial Update and Interview With President and CEO Richard Gabriel Are Now Available on the Internet

SARASOTA, FL -- (MARKET WIRE) -- August 28, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that an archived transcription of the Company's quarterly update of activities that was conducted on Tuesday, August 22, is now available on Brighttalk.com, and an interview with Company President and CEO Richard Gabriel, conducted on August 23, is available on Market News First.

"We are quite enthusiastic about using the Internet to demonstrate how we are delivering shareholder value," stated Richard Gabriel, DNAPrint Genomics President and Chief Executive Officer. "It is cost-effective and has tremendous reach. We will be using these platforms -- Brighttalk.com and Market News First -- in the future as we share our latest research findings and company milestones."

Mr. Gabriel updated listeners on funding and research activities related to its wholly owned subsidiaries DNAPrint Pharmaceuticals (U.S.) and Ellipsis Biotherapeutics, Inc. (Canada), and the proposed IPO for Biofrontera, A.G. of Germany, in which the Company owns an 18.3% stake.

Mr. Gabriel also elaborated on the DNAPrint's new relationship with Emory University, which is noteworthy in that it is the first time that genetic ancestry technology has been used in a clinical environment with the emphasis on drug diagnostic discovery and development.

Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer, outlined the Company's ongoing research in pharmacogenomics, and Chief Financial Officer Karen Surplus gave a financial summary, noting that revenues for the six-month period ending June 30, 2006 were $1.256 million, compared to $589,000 for the same period of 2005, an increase of 113%. Complete details are available in the archived Webcast.

To access the archived Webcast, interested parties should go to http://brighttalk.com/event/DNAPrint/e2ef524fbf-97-intro, and log in. Free registration is required for the site. The live Webcast will be available free of charge for 45 days.

Mr. Gabriel also gave an interview on Market News First, noting the strong interest in DNAPrint's AncestrybyDNA™ product and the ongoing forensic uses of DNAWITNESS™, which is being employed by New Scotland Yard in the United Kingdom as part of an effort to capture the so-called Minstead Rapist. Mr. Gabriel also tied together the work that the Company has been doing since 1999 on human genetic ancestry and pharmaceutical discovery and development by providing the audience with a historical development of the technology and why the Company focused on genealogy and forensics and how they are now applying it to drugs and diagnostics.

"Market News First provides an exceptional format to explain the rationale for developing genealogy and forensic services and products for our investors and listeners. I am especially appreciative of the enthusiastic reception and interest in this new and exciting field of development in pharmaceuticals," Mr. Gabriel said.

The Market News First interview with Mr. Gabriel is available for download or streaming on the Market News First website by going to http://www.mn1.com/members/modules.php?name=Downloads&d_op=viewdownloaddetails&lid=316&ttitle=MN1.COM%20::%20DNAprint%20Genomics,%20Inc.%20(DNAG.OB)%2 0Interview%20(08/23/06).

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS™, RETINOME™, ANCESTRYbyDNA™ and EURO-DNA™. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Contact Information

  • Company Contact:
    Richard Gabriel
    CEO and President
    941 366-3400

    or

    Ron Stabiner
    The Wall Street Group, Inc.
    212-888-4848